Characterization of Human Anti-Dengue NS1 Monoclonal Antibodies Derived from Patients Infected with DENV-2
Issued Date
2022-01-01
Resource Type
ISSN
13446304
eISSN
18842836
Scopus ID
2-s2.0-85123813887
Pubmed ID
34053951
Journal Title
Japanese Journal of Infectious Diseases
Volume
75
Issue
1
Start Page
24
End Page
30
Rights Holder(s)
SCOPUS
Bibliographic Citation
Japanese Journal of Infectious Diseases Vol.75 No.1 (2022) , 24-30
Suggested Citation
Kowaboot S. Characterization of Human Anti-Dengue NS1 Monoclonal Antibodies Derived from Patients Infected with DENV-2. Japanese Journal of Infectious Diseases Vol.75 No.1 (2022) , 24-30. 30. doi:10.7883/yoken.JJID.2020.1071 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/86683
Title
Characterization of Human Anti-Dengue NS1 Monoclonal Antibodies Derived from Patients Infected with DENV-2
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
Mouse antibodies specific to dengue NS1 have been widely investigated for their crossreactivity with several human biomolecules. This is the first study demonstrating the cross-reactivity of human monoclonal antibodies (HuMAbs) specific to dengue NS1 isolated from patients infected with dengue virus serotype-2 (DENV-2). Nine anti-NS1 HuMAbs, which were mainly derived from patients in convalescent-phase after secondary infection of DENV-2, were characterized. Their cross-reactivity with plasminogen, thrombin, and endothelial cells was investigated, following which plasmin-formation assays were performed. All anti-NS1 HuMAbs exhibited cross-reactivity with human plasminogen (Plg), but not with thrombin or endothelial cells. Moreover, all HuMAbs exhibiting cross-reactivity with Plg converted Plg to plasmin in the plasmin-formation assay. These results suggest the implications and drawbacks of using anti-NS1 antibodies in immunotherapy.